JP2022546454A5 - - Google Patents
Info
- Publication number
- JP2022546454A5 JP2022546454A5 JP2022513347A JP2022513347A JP2022546454A5 JP 2022546454 A5 JP2022546454 A5 JP 2022546454A5 JP 2022513347 A JP2022513347 A JP 2022513347A JP 2022513347 A JP2022513347 A JP 2022513347A JP 2022546454 A5 JP2022546454 A5 JP 2022546454A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- item
- use according
- cancer
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025010364A JP2025061790A (ja) | 2019-08-30 | 2025-01-24 | がん処置のためのｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962894047P | 2019-08-30 | 2019-08-30 | |
| US62/894,047 | 2019-08-30 | ||
| US201962895320P | 2019-09-03 | 2019-09-03 | |
| US62/895,320 | 2019-09-03 | ||
| US201962916935P | 2019-10-18 | 2019-10-18 | |
| US62/916,935 | 2019-10-18 | ||
| PCT/US2020/048500 WO2021041878A1 (en) | 2019-08-30 | 2020-08-28 | Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025010364A Division JP2025061790A (ja) | 2019-08-30 | 2025-01-24 | がん処置のためのｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022546454A JP2022546454A (ja) | 2022-11-04 |
| JP2022546454A5 true JP2022546454A5 (https=) | 2023-09-05 |
Family
ID=74683405
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513347A Pending JP2022546454A (ja) | 2019-08-30 | 2020-08-28 | がん処置のためのｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン |
| JP2025010364A Pending JP2025061790A (ja) | 2019-08-30 | 2025-01-24 | がん処置のためのｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025010364A Pending JP2025061790A (ja) | 2019-08-30 | 2025-01-24 | がん処置のためのｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220195065A1 (https=) |
| EP (1) | EP4021943A4 (https=) |
| JP (2) | JP2022546454A (https=) |
| KR (1) | KR20220054649A (https=) |
| CN (2) | CN114630842A (https=) |
| AU (1) | AU2020337999A1 (https=) |
| BR (1) | BR112022003707A2 (https=) |
| CA (1) | CA3152776A1 (https=) |
| CL (1) | CL2022000495A1 (https=) |
| CO (1) | CO2022003580A2 (https=) |
| IL (1) | IL290871A (https=) |
| MX (1) | MX2022002524A (https=) |
| PE (1) | PE20221404A1 (https=) |
| WO (1) | WO2021041878A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| US20230416402A1 (en) * | 2022-03-03 | 2023-12-28 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2 |
| AR134292A1 (es) * | 2023-11-13 | 2025-12-17 | Dragonfly Therapeutics Inc | Métodos para tratar el cáncer mediante el uso de proteínas de unión multiespecíficas que se unen a nkg2d, cd16 y her2 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| RU2769282C2 (ru) * | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| CN110944661A (zh) * | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| BR112020007002A2 (pt) * | 2017-10-10 | 2020-11-17 | Sanofi | anticorpos anti-cd38 e métodos de uso |
| BR112020015994A2 (pt) * | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) * | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| EA202091888A1 (ru) * | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
-
2020
- 2020-08-28 AU AU2020337999A patent/AU2020337999A1/en active Pending
- 2020-08-28 CA CA3152776A patent/CA3152776A1/en active Pending
- 2020-08-28 MX MX2022002524A patent/MX2022002524A/es unknown
- 2020-08-28 CN CN202080075846.5A patent/CN114630842A/zh active Pending
- 2020-08-28 EP EP20859452.3A patent/EP4021943A4/en active Pending
- 2020-08-28 CN CN202410920352.2A patent/CN118924895A/zh active Pending
- 2020-08-28 PE PE2022000343A patent/PE20221404A1/es unknown
- 2020-08-28 KR KR1020227010394A patent/KR20220054649A/ko active Pending
- 2020-08-28 BR BR112022003707A patent/BR112022003707A2/pt unknown
- 2020-08-28 JP JP2022513347A patent/JP2022546454A/ja active Pending
- 2020-08-28 WO PCT/US2020/048500 patent/WO2021041878A1/en not_active Ceased
-
2022
- 2022-02-24 IL IL290871A patent/IL290871A/en unknown
- 2022-02-28 US US17/682,367 patent/US20220195065A1/en not_active Abandoned
- 2022-02-28 CL CL2022000495A patent/CL2022000495A1/es unknown
- 2022-03-25 CO CONC2022/0003580A patent/CO2022003580A2/es unknown
-
2025
- 2025-01-24 JP JP2025010364A patent/JP2025061790A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022546454A5 (https=) | ||
| JP7257364B2 (ja) | 抗ｃｄ１３７抗体 | |
| JP7436477B2 (ja) | ＴＧＦ－β受容体融合タンパク質医薬組成物およびその使用 | |
| JP7352973B2 (ja) | 二重特異性抗体及びその使用 | |
| JP6967515B2 (ja) | Ｐｄ−１抗体 | |
| JP2020015719A (ja) | ペルツズマブ変異体及びその評価 | |
| CN102884084B (zh) | 抗her2抗体及组合物 | |
| JP2022513420A5 (https=) | ||
| JP7728185B2 (ja) | 共有結合型多重特異性抗体 | |
| JP2011501656A5 (https=) | ||
| JP2023549537A5 (https=) | ||
| CN114761433B (zh) | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 | |
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JP2022532991A5 (https=) | ||
| CN113135995B (zh) | 抗her3单克隆抗体及其应用 | |
| WO2019076277A1 (zh) | 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途 | |
| CA3180188A1 (en) | Anti-flt3 antibodies and compositions | |
| TW201925230A (zh) | 以抗egfr療法治療癌症的組成物及方法 | |
| WO2019114793A1 (zh) | 一种egfr抗体及其制备方法和应用 | |
| CN103417965B (zh) | 一种含有抗vegf抗体的药物组合物 | |
| JP2026506070A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| CN104861068A (zh) | 一种全人源抗her3抗体及含有该抗体的组合物和其用于制备治疗her3相关疾病的药物中的用途 | |
| WO2023093744A1 (zh) | 一种双特异性抗原结合蛋白 | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| KR20220153615A (ko) | 암의 치료 및/또는 예방을 위한 의약품 |